Germany | NATO DIANA Energy & Power 2026
Dual-action wound care against multidrug-resistant infections
NATO DIANA 2026 Cohort
Lysando Innovations Lab GmbH specializes in developing dual-action wound care solutions specifically designed to combat multidrug-resistant (MDR) infections. Their core technology, Artilysin®, offers a novel approach to treating complex bacterial infections that are unresponsive to conventional antibiotics. This innovation is crucial for addressing critical health threats in both civilian and military contexts.
A key differentiator for Artilysin® is its ability to combat multidrug-resistant strains and even bacterial persisters, which are notoriously difficult to eradicate with traditional antibiotics. Unlike broad-spectrum antibiotics, Artilysins offer a targeted approach that minimizes disruption to the host's natural microbiome, promoting faster healing and reducing secondary infections. This precision makes it a superior option for complex wound management.
The defense sector should care deeply about Lysando's technology due to the escalating threat of multidrug-resistant infections in military operations and humanitarian aid missions. Battlefield injuries, surgical procedures, and prolonged deployments create environments where MDR pathogens thrive, leading to severe complications, prolonged recovery times, and significant operational costs. Artilysin® offers a critical solution to enhance soldier resilience and readiness.
The return on investment for adopting Artilysin® would be significant, primarily through reduced morbidity and mortality rates among service members, leading to fewer medical evacuations and faster returns to duty. While initial procurement costs may exist, these would be offset by decreased long-term treatment expenses for chronic or resistant infections, improved operational readiness, and enhanced force protection. Preventing just one severe MDR infection could save millions in healthcare costs and personnel time.
Based on the extensive research, 100 associated clinical results, and publications dating back to 2014 with recent news in 2023, Lysando's Artilysin® technology appears to be at a high Technology Readiness Level (TRL 7-8). This indicates that a system prototype has been demonstrated in an operational environment, or the actual system is completed and qualified through test and demonstration. It is likely nearing or in advanced stages of market readiness for specific applications.
Lysando Innovations Lab GmbH is a German biotech firm pioneering Artilysin® technology for dual-action wound care against multidrug-resistant infections. Their engineered endolysins effectively target and eliminate Gram-negative pathogens, including highly resistant strains, while preserving the microbiome. This innovation offers a critical solution for enhancing military medical readiness and human resilience, addressing a significant threat to global health and defense operations.